Connor, Clark & Lunn Investment Management (CC&L)’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-42,649
| Closed | -$1.86M | – | 1610 |
|
|
2023
Q3 | $1.86M | Sell |
42,649
-74,502
| -64% | -$3.25M | 0.01% | 640 |
|
|
2023
Q2 | $4.23M | Sell |
117,151
-19,335
| -14% | -$699K | 0.02% | 433 |
|
|
2023
Q1 | $5.07M | Buy |
+136,486
| New | +$5.07M | 0.03% | 367 |
|
|
2022
Q1 | – | Sell |
-20,751
| Closed | -$3.04M | – | 1262 |
|
|
2021
Q4 | $3.04M | Buy |
+20,751
| New | +$3.04M | 0.01% | 438 |
|
|
2021
Q2 | – | Sell |
-4,448
| Closed | -$762K | – | 1138 |
|
|
2021
Q1 | $762K | Buy |
4,448
+1,435
| +48% | +$246K | ﹤0.01% | 733 |
|
|
2020
Q4 | $662K | Buy |
+3,013
| New | +$662K | ﹤0.01% | 689 |
|
|
2017
Q3 | – | Sell |
-15,900
| Closed | -$58K | – | 939 |
|
|
2017
Q2 | $58K | Buy |
15,900
+100
| +0.6% | +$365 | ﹤0.01% | 798 |
|
|
2017
Q1 | $82K | Buy |
+15,800
| New | +$82K | ﹤0.01% | 863 |
|